Subject(s)
Humans , Male , Female , Immunotherapy, Active , Papillomavirus Infections/prevention & control , Uterine Cervical Neoplasms/prevention & control , Vaccines, Synthetic/administration & dosage , Tumor Virus Infections/prevention & control , Uterine Cervical Neoplasms/epidemiology , Papillomaviridae , Vaccines, Synthetic , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/standardsSubject(s)
Humans , Male , Female , Tumor Virus Infections/prevention & control , Papillomavirus Infections/prevention & control , Uterine Cervical Neoplasms/prevention & control , Papillomaviridae , Vaccines, Synthetic/standards , Immunotherapy, Active , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/classification , Vaccines, SyntheticABSTRACT
The increasing number of pertussis cases reported on the last twenty years and the existence of new acellular vaccines reinforce the need of research for experimental models to assure the quality of available pertussis vaccines. In this study, allotments of whole-cell and acellular pertussis vaccines were tested through the Intranasal Challenge Model (INM) using conventional NIH mice. The results have been compared to those achieved by the "Gold standard" Intracerebral Challenge Model (ICM). In contrast to ICM, INM results did not show intralaboratorial variations. Statistical analysis by Anova and Ancova tests revealed that the INM presented reproducibility and allowed identification and separation of different products, including three-component and four-component accellular pertussis vaccines. INM revealed differences between pertussis vaccines. INM provides lower distress to the mice allowing the reduction of mice number including the possibility of using conventional mice (less expensive) under non-aseptic environment. Thus, INM may be used as an alternative method of verifying the consistence of allotment production, including acellular pertussis vaccines.
Subject(s)
Animals , Male , Female , Mice , Bordetella pertussis/immunology , Pertussis Vaccine/immunology , Whooping Cough/immunology , Administration, Intranasal , Disease Models, Animal , Immunity, Cellular , Pertussis Vaccine/adverse effects , Pertussis Vaccine/standards , Reproducibility of Results , Time Factors , Vaccines, Acellular/adverse effects , Vaccines, Acellular/immunology , Vaccines, Acellular/standards , Vaccines, Synthetic/adverse effects , Vaccines, Synthetic/immunology , Vaccines, Synthetic/standards , Whooping Cough/prevention & controlABSTRACT
El objetivo de este trabajo es contribuir a conocer la respuesta inmune a la vacuna de origan cubano contra hepatitis B (Lab. Hber BioVac HB). Sobre un grupo de 250 inscriptos, se realizó control prevacunal por E.I. A. a 239 alumnos (19/25 años) y 11 odontólogos (10: 24/28 años y 1 mayor 45 años) encontrándose sólo un reactivo positivo para anti HB, que se evaluó negativo para otros marcadores. Se utilizaron vacunas pertenecientes a los lotes No. 55300 y 57700 cedidas por el M.S.P.M.A. y A.S. de la N. aplicando un plan de inmunización de 0 - 30 - y 180 días. No concurrieron a la vacunación 50 alumnos y 2 odontólogos. Se obtuvo una seroconversión del 97,9 por ciento a los 120 días